The Emmes Company, LLC

The Emmes Company, LLC, headquartered in Rockville, Maryland, is a for-profit clinical research organization that delivers biostatistical analysis, data management, clinical trial coordination, regulatory support, and clinical research infrastructure services to the National Institutes of Health and related federal agencies as a prime contractor on 95% of recent awards. The company operates without SBA set-aside designations and competes on a full-and-open basis across its federal footprint, holding a portfolio of single-award Indefinite Delivery Vehicles worth several billion dollars.

Emmes' customer concentration sits almost entirely within the NIH ecosystem. The top five customer agencies by count account for 63% of awards, anchored by the National Institute on Drug Abuse (91 awards, $498.6 million potential value), the National Institute of Allergy and Infectious Diseases (42 awards, $1.37 billion), the National Institute of Child Health and Human Development (41 awards, $192.7 million), NIH broadly (41 awards, $2.1 million), and the National Human Genome Research Institute (38 awards, $11.2 million). However, the top-five ranking by dollar potential value diverges substantially: the National Institute of Diabetes and Digestive and Kidney Diseases anchors 7 awards worth $3.98 billion in combined potential value, followed by NIAID at $1.37 billion, NIDA at $498.6 million, the National Cancer Institute at $387.4 million, and the NIH Office of Logistics and Acquisition Operations at $372.7 million. The NIDDK concentration reflects long-term cooperative agreements for registry and data coordinating center work. Across all sources, Emmes serves 23 distinct federal customer agencies, but 91% of potential value concentrates in five agencies, all within HHS.

Emmes holds major single-award IDVs anchoring its federal business. The NIDA Data, Statistics, and Clinical Trial Support Center IDV (N01DA-22-2253), valued at $44.3 million with ceiling through September 4, 2027, has generated 26 delivery orders totaling approximately $29.5 million as of May 2025, supporting substance abuse treatment trials including studies on opioid use disorder, polysubstance use, medication-assisted treatment interventions, and the HEAL (Helping to End Addiction Long-Term) initiative. The NIAID Comprehensive and Rapid Response for NIAID Research Programs (CARRRP) IDV, valued at $545.5 million with ceiling through August 31, 2028, provides biostatistical, data management, regulatory, and bioinformatics support across infectious disease and vaccine research. The NIDA Clinical Coordinating Center for Clinical Trials Network IDV, a single-award vehicle valued at $49.5 million with ceiling through August 14, 2029, coordinates multi-site clinical trials and supports data coordinating center functions. The NHGRI Clinical Research Support and Collaboration contract, a $4 million IDV with ceiling through December 31, 2026, funds task orders for statistical expertise, regulatory support, and Data Safety and Monitoring Board services. The NIH All of Us Research Program IRB IDV, ceiling through March 24, 2023, carries $1.1 million in potential value for research program support. Representative prime contracts include a $50.9 million definitive contract with the National Cancer Institute for logistical and IT support to the NCI Central Individual Review Board (ceiling August 31, 2029); a $37.1 million definitive contract with NIAID for the Allergy and Asthma Statistical & Clinical Coordinating Center (ceiling January 31, 2027, now terminated for convenience); a $30.1 million definitive contract with the National Eye Institute for development, statistical design, monitoring, and coordination of vision clinical trials and epidemiology research (ceiling October 31, 2026); and a $16.5 million definitive contract with NIDA for a Data Coordinating Center supporting the National NeuroHIV Tissue Consortium (ceiling August 6, 2028). Emmes also holds federal grant vehicles: a cooperative agreement with the National Institute of Diabetes and Digestive and Kidney Diseases valued at approximately $3 million (FY basis) to serve as the Data and Statistical Coordinating Center for the Collaborative Islet Transplantation Registry (CITR) for 2022–2027.

Activity has remained stable year over year across the past five years (22 awards in 2022 to 27 in 2024, declining to 25 in 2025 and 13 in the first six months of 2026, a partial-year snapshot). Thirty-seven awards with ultimate completion dates within the next twenty-four months carry combined potential value of $581.6 million and face recompete within that window, representing substantial pipeline risk for the vendor and recompete opportunity for competitors on major NIDA, NIAID, NIDDK, and NCI vehicles.

SCI-reported invoicing on federal service contracts above the $150,000 threshold totaled $260.5 million across FY2022–FY2024 (not the vendor's total federal revenue, which is substantially larger given exclusion of grants, products, and sub-million contracts from SCI reporting). Prime contract invoicing grew modestly: $85.4 million in FY2022 (376 FTEs), $87 million in FY2023 (395 FTEs), and $88.1 million in FY2024 (415 FTEs). On federal services contracts captured in SCI, median government-paid rates ran around $129.28 per hour, with senior labor pricing through $217.99 per hour and entry-level labor near $61.27 per hour. Across SCI-reportable prime contracts, subcontractors performed approximately 1% of total contractor hours; Emmes named 15 distinct subcontractors across the three-year SCI window, indicating a model centered on self-performed delivery rather than subcontractor-heavy execution.

Emmes subcontracts to other primes on a limited basis. Recent sub-awards include data management and statistical analysis support to Gap Solutions, Inc. for the CIVICS Statistical, Data Management and Coordination Center (multiple task orders 2025–2026); statistical design and analysis support to Regency Consulting Inc. for CIVICS SDMCC (April 2025); data management and statistical analysis support to Digital Infuzion, LLC for CIVICS SDMCC (September 2024, September 2025); clinical trial data management and statistical support to Weems Design Studio, Inc. for an NIAID H5N1 vaccine clinical trial (December 2024); and vaccine trial support work to the International AIDS Vaccine Initiative (March–April 2025). Grant sub-awards include data coordinating center services as a sub-recipient under The Medical College of Wisconsin (Blood and Marrow Transplant Clinical Trials Network DCC and Cure Sickle Cell initiatives, multiple awards 2024–2026) and sub-recipient work under Trustees of Dartmouth College for the Northeast Node of the National Drug Abuse Treatment Clinical Trials Network (August 2025). The sub-award footprint is modest relative to prime volume, consistent with the SCI finding that the vendor self-performs the majority of its delivery.

Emmes operates two named subsidiaries: Emmes Endpoint Solutions, LLC (Self Certified Small Disadvantaged Business) and Essex Management LLC. The SDB designation on the subsidiary does not appear to anchor a material set-aside strategy in the visible award record, where the vast majority of prime awards carry no set-aside designation and compete full-and-open against other federal contractors.

Emmes' capability portfolio is concrete and deep within clinical research infrastructure. The vendor delivers end-to-end data coordinating center services (recruitment tracking, protocol monitoring, database design and validation, statistical analysis, protocol adherence monitoring, quality assurance), clinical trial coordination and management (site management, enrollment and retention support, regulatory submissions), biostatistical analysis and study design, regulatory support for Investigational New Drug and Investigational Device Exemption submissions, Data Safety and Monitoring Board operations, epidemiological and observational research support, and electronic data capture system design and training. Recent concrete work includes management and support for NIDA's substance abuse treatment clinical trials (multiple task orders under the $44.3 million IDV); data coordinating center services for pediatric health disparities research under NICHD (multiple awards, Total Small Business set-aside); clinical coordinating center operations for NIDA's Clinical Trials Network spanning opioid use disorder, stimulant use, cocaine use, and related conditions; statistical expertise and protocol monitoring for NHGRI genomic medicine research; logistical and IT support to the NCI Central Individual Review Board; allergy and asthma statistical and clinical coordination for NIAID; and vision research trial coordination for the National Eye Institute. The vendor's footprint also extends to FDA clinical site monitoring work (multiple awards 2021–2023, now inactive) and NIH All of Us Research Program IRB support.